Search Patents
  • Publication number: 20120270914
    Abstract: A split luciferase-based sensor system was developed to noninvasively monitor and image phosphorylation-mediated c-Myc activation, in which the complementation of the split FL is induced by phosphorylation-mediated interaction between GSK3? and c-Myc. The complemented luciferase activity resulting from this interaction is specific to c-Myc phosphorylation and correlated with the steady-state and temporal regulation of c-Myc phosphorylation in cell culture. The sensor system also allows monitoring of c-Myc—targeted drug efficacy in intact cells and living animals. This new imaging sensor can provide insight into the role of functional c-Myc in cancer biology and is useful for the discovery and development of specific anti-c-Myc drugs.
    Type: Application
    Filed: April 25, 2012
    Publication date: October 25, 2012
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Hua Fan-Minogue, Sanjiv S. Gambhir
  • Publication number: 20140030725
    Abstract: A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.
    Type: Application
    Filed: November 12, 2012
    Publication date: January 30, 2014
    Applicant: PROMEGA CORPORATION
    Inventor: Promega Corporation
  • Patent number: 6956114
    Abstract: The present invention relates to the field of DNA recombinant technology. More specifically, this invention relates to fusion proteins comprising an ATP generating polypeptide joined to a polypeptide that converts ATP into a detectable entity. Accordingly, this invention focuses on sulfurylase-luciferase fusion proteins. This invention also relates to pharmaceutical compositions containing the fusion proteins and methods for using them.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: October 18, 2005
    Assignee: '454 Corporation
    Inventors: Maithreyan Srinivasan, Michael Reifler
  • Publication number: 20150044709
    Abstract: The present invention is concerned with test systems for determining the activity of neurotoxin polypeptides. Specifically, it relates to a polynucleotide encoding a single chain luciferase fusion polypeptide comprising: (i) a LuxB subunit, (ii) a linker comprising a neurotoxin cleavage site, and (iii) a LuxA subunit and a polypeptide encoded by the polynucleotide. Further provided in accordance with the invention are a vector and a host cell comprising the polynucleotide. Moreover, the present invention relates to a method for determining a proteolytically active neurotoxin polypeptide in a sample and a kit for carrying out the method.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 12, 2015
    Inventor: Karl-Heinz Eisele
  • Publication number: 20110283373
    Abstract: A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.
    Type: Application
    Filed: May 11, 2011
    Publication date: November 17, 2011
    Inventors: Brock BINKOWSKI, Braeden BUTLER, Lance P. ENCELL, Frank FAN, Brad HOOK, Paul OTTO, Gediminas VIDUGIRIS, Susan WIGDAL, Kristopher ZIMMERMAN
  • Publication number: 20140242574
    Abstract: There has been a demand for a codon-optimized gene for the mutated catalytic domain of Oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and Escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kDa protein. The invention provides a polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2. According to the invention, bis-coelenterazine is used as a substrate coelenterazine analogue suitable for the photoprotein encoded by the polynucleotide comprising the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 28, 2014
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Junichi SATO
  • Publication number: 20080132427
    Abstract: The invention provides proliferative response indicator cell having a vertebrate cell having a luciferase encoding nucleic acid and a heterologous proliferation factor receptor encoding nucleic acid, wherein each of the encoding nucleic acids are operationally linked to expression elements for co-expression of a luciferase polypeptide and a heterologous proliferation factor receptor. The invention also provides a method of determining a cell proliferative response to a proliferation factor.
    Type: Application
    Filed: July 20, 2007
    Publication date: June 5, 2008
    Inventors: Yao Zhuang, Zheng Hu
  • Patent number: 9200046
    Abstract: The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 1, 2015
    Assignee: CORNELL UNIVERSITY
    Inventors: Rajiv Ratan, Irina Gazaryan, Natalya A. Smirnova
  • Publication number: 20030157519
    Abstract: The invention relates to compositions comprising a first fusion protein comprising a first polypeptide domain and a R. reniformis luciferase and a second fusion protein comprising a second polypeptide domain and a R. reniformis GFP. The invention also relates to compositions comprising one or more polynucleotides encoding a first fusion protein comprising a first polypeptide domain and a R. reniformis luciferase and a second fusion protein comprising a second polypeptide domain and a R. reniformis GFP. The invention also relates to methods and kits for detecting protein-protein interactions, determining the location of a protein-protein interaction, identifying cells wherein there is a protein-protein interaction of interest, and screening for a candidate modulator that increases or decreases the amount of a protein-protein interaction.
    Type: Application
    Filed: October 4, 2002
    Publication date: August 21, 2003
    Applicant: Stratagene
    Inventors: Vivan Q. Zhang, Peter E. Vaillancourt
  • Publication number: 20130318645
    Abstract: A method, called GETWISE, for targeting mouse genes is described. GETWISE is designed to increase the frequency of homologous recombination, facilitate screening, widen the applicability of engineered animals and circumvent intrinsic gene targeting problems. GETWISE utilizes the principle of modulating gene expression by targeting tetracycline-responsive elements into a specific locus. In GETWISE alleles, control of gene expression is transferred from the endogenous to a tetracycline-inducible promoter. Endogenous promoters now control expression of the reporter gene luciferase. Breeding of GETWISE carriers with tTA/rtTA carriers enables investigators to modulate gene expression in a ubiquitous or tissue-specific manner, depending on the presence of doxycycline. GETWISE enables the study of loss or gain of gene expression in any tissue of choice within a single mouse strain. GETWISE enables the analysis of the gene expression pattern with the luciferase assay.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 28, 2013
    Inventor: Georgia Regent University
  • Publication number: 20140303035
    Abstract: The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.
    Type: Application
    Filed: November 7, 2012
    Publication date: October 9, 2014
    Inventors: Sean Burns, David Altshuler, Amedeo Vetere
  • Patent number: 7572629
    Abstract: A gene construct incorporating any of at least two luciferase genes which emit lights with different colors using an identical substrate such that the gene can be stably expressed in mammalian cells.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: August 11, 2009
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Yoshihiro Ohmiya, Yoshihiro Nakajima
  • Patent number: 5851796
    Abstract: A tetracycline-regulated system which provides autoregulatory, inducible gene expression in cultured cells and transgenic animals is described. In the autoregulatory plasmid pTet-tTAk, a modified tTA gene called tTAk was placed under the control of Tetp. Tetracycline prevents tTA from binding to Tetp, preventing expression of both tTA and luciferase. This negative feedback cycle ensures that little or no tTA is produced in the presence of tetracycline, thereby reducing or eliminating possible toxic effects. When tetracycline is removed, however, this strategy predicts that tiny amounts of tTA protein (which may result from the leakiness of the minimal promoter), will bind to Tet-op and stimulate expression of the tTAk gene. A positive feedforward loop is initiated which in turn leads to higher levels of expression of tTA and thus, luciferase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignee: Yale University
    Inventor: David G. Schatz
  • Publication number: 20080187942
    Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.
    Type: Application
    Filed: October 1, 2007
    Publication date: August 7, 2008
    Inventor: James L. Brown
  • Patent number: 6720153
    Abstract: This invention is directed to a bioassay for determining the functionality of parathyroid hormone compounds. More particularly, this invention is directed to a bioassay wherein the compound to be tested is added to a culture of parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple c-AMP responsive elements.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: April 13, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Richard F. Labaudiniere, Kin T. Yu, Gregg R. Crumley, Clarence C. Morse
  • Patent number: 7109315
    Abstract: Isolated and purified nucleic acids encoding green fluorescent proteins from Renilla reniformis and the green fluorescent protein encoded thereby are also provided. Mutants of the nucleic acid molecules and the modified encoded proteins are also provided. Compositions and combinations comprising the green fluorescent proteins and/or the luciferase are further provided.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 19, 2006
    Assignees: Prolone, Ltd.
    Inventors: Bruce Bryan, Christopher Szent-Gyorgyi, William Szczepaniak
  • Patent number: 8293879
    Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: October 23, 2012
    Assignee: Diagnostic Hybrids, Inc.
    Inventor: James L. Brown
  • Patent number: 8926981
    Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 6, 2015
    Assignee: Diagnostic Hybrids, Inc.
    Inventor: James L. Brown
  • Publication number: 20040137611
    Abstract: The invention relates to methods and compositions which utilize the emission of light to monitor changes in microenvironments involving cells. The invention is especially useful for monitoring exocytotic activity such as detecting quantal release of synaptic vesicles. Fusion proteins of Cypridina luciferase and synaptotagmin-I or VAMP/synaptobrevin-2 were targeted to synaptic vesicles and, upon exocytosis, formed light-emitting complexes with luciferin present in the extracellular medium. Photon emissions in the presence of a depolarizing stimulus can be observed with these systems. pH-sensitive mutants of green fluorescent protein are also provided, which are useful for visualizing exocytosis and for imaging and measuring the pH of intracellular compartments.
    Type: Application
    Filed: September 30, 2003
    Publication date: July 15, 2004
    Inventors: Gero Miesenbock, Dino De Angelis, James E. Rothman
  • Publication number: 20100055039
    Abstract: The embodiments of the present disclosure encompass methods for non-invasive in vivo bioluminescence imaging that allow the dynamics of stem cell behavior to be followed in a manner not possible using conventional retrospective static histological analyses. By imaging luciferase-generated bioluminescence activity emanating from isolated stem cells, for example, real time quantitative and kinetic analyses can show that donor-derived muscle stem cells may proliferate and engraft rapidly after injection until homeostasis is reached. In addition, the response of the stem cells to injury and participation in the regenerative response can be monitored over time. Other aspects of the disclosure encompasses methods for determining the suitability of a stem cell for tissue replacement, methods for repairing muscle injury, and methods for isolating muscle stem cells from a tissue sample.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 4, 2010
    Inventors: Regis Doyonnas, Alessandra Sacco, Helen M. Blau